Clinical Trial Detail

NCT ID NCT03407976
Title Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Utah
Indications

gastric adenocarcinoma

Advanced Solid Tumor

colorectal cancer

transitional cell carcinoma

gastroesophageal junction adenocarcinoma

Therapies

Pembrolizumab + Rivoceranib

Age Groups: adult senior

No variant requirements are available.